Advancing Point of Care Tissue Imaging with Genesis Imaging System

Author: Gabrielle Flora, Associate Director, BRC
Click for Information and Recordings

 Dr. Christian Schwentner

Dr. Christian Schwentner

          Fast, accurate tissue imaging is critical to today’s point-of-care diagnostics. On September 30, the BioPharma Research Council (BRC) hosted a webinar focused on an emerging approach to tissue imaging of prostate cancer biopsies. Dr. Christian Schwentner, Professor of Urology and Urological Oncology, University Hospital in Tuebingen, Germany, presented on the Genesis Imaging System during the webinar: Advancing Tissue Imaging: Non-destructive, Stain-free, Novel Techniques for Digital Pathology and Research.

          “I, as a clinician, strongly believe in point-of-care diagnostics,” says Dr. Schwentner. He explained his use of these new imaging techniques during this webinar and demonstrated how it applies to his research.

          “Prostate cancer is the most frequent cancer in males, and there is a significant amount of overdiagnosis and overtreatment,” he says. Because prostate cancer is slow-growing, sometimes no treatment is better than any treatment. He focuses on using Genesis’ new imaging tools to appropriately diagnose patients, classify their level of cancer precisely from low to intermediate to high, and treat with correct therapies.

          “There is an urgent need for standardized, automated reporting,” says Dr. Schwentner, “and we are the first to provide stain-free, 3D, quantitative imaging. Non-stained imaging can provide anatomical details without ruining the processed tissue. Genesis is the ideal tool for intraoperative decision making.” Using this new technology, Dr. Schwentner is able to intraoperatively visualize all microanatomy and compare non-cancerous to cancerous regions in the prostate.

         Developed by Genesis Imaging Services, this new technology is rapidly advancing point-of-care biopsy to diagnosis. It is available for research purposes at this time, according to Mathieu Petitjean, Ph.D., President of Mednest LLC and Pharmanest LLC.

 Mathieu Petitjean

Mathieu Petitjean

          “Everything we learn using this technology we share, and it has value across many different therapeutic areas,” says Dr. Petitjean. From a research perspective, this imaging tool allows surgeons and researchers to look at a wide range of signals, or biomarkers, which is significant and applicable to many diseases.
For more information, please visit www.genesisimagingservices.com

This webinar was presented as part of the BRC's ongoing series, D3D: Data, Drugs, and Diagnostics.
Click Here for Recordings          www.biopharmaresearchcouncil.org